Journal for Immunotherapy of Cancer

Article	Citations
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future	301
Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity	262
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometri	166
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events	151
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?	146
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice	144
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer	142
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy	132
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies	132
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer	128
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation	127
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers	126
Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review	121
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer	121
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma	119
Acute kidney injury in patients treated with immune checkpoint inhibitors	118
Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer	118
CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer	116
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead	112
Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma	111
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma	110
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer	109
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma	109
Therapeutic depletion of CCR8+tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy	106
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial	101

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial	100
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors	99
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma	96
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images	96
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial	93
Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1–mediated immunoescape via STING-IFN signaling and extracellular vesicles	92
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma	91
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy	91
Deregulation of HLA-I in cancer and its central importance for immunotherapy	91
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies	89
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers	87
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies	87
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial	87
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemothera	85
Rethinking immune checkpoint blockade: ‘Beyond the T cell’	85
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma	84
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1	84
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy	84
A signature for pan-cancer prognosis based on neutrophil extracellular traps	84
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.	81
Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma	80
S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation	80
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies	80
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors	78
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targ	78
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer	77
Severity of COVID-19 in patients with lung cancer: evidence and challenges	76
STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment	76
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)	76
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages	76
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer	76
Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy	76
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade	75
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma	75
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors	75
Tumors establish resistance to immunotherapy by regulating Tregrecruitment via CCR4	75
Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy	74
Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer	74
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer	73
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma	73
Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer	72
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma	72
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma	72
Considerations for treatment duration in responders to immune checkpoint inhibitors	71
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck	71
Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis	70
Immunogenic ferroptosis and where to find it?	69
Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival	69
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity	69
CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype	68

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL	68
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial	68
LRP1Bmutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types	68
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma	67
Aged neutrophils form mitochondria-dependent vital NETs to promote breast cancer lung metastasis	67
CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer	67
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia	66
Role of Fcγ receptors in HER2-targeted breast cancer therapy	66
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)	65
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer	65
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy	65
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial	64
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study	63
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities	62
GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma	61
Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function	61
Strategies for improving the management of immune-related adverse events	61
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)	60
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial	59
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy inKRAS-mutated non-small cell lung cancer withSTK11,KEAP1,orTP53comutations: subgroup results from the p	59
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas	59
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies	58
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma	57
Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3	57
Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis	57
Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer	56
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy	56
Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite	56
Neutrophils in the era of immune checkpoint blockade	56
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma	55
Interleukin-15 and cancer: some solved and many unsolved questions	55
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study	55
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes	54
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis	54
Obesity diminishes response to PD-1-based immunotherapies in renal cancer	54
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial	54
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity	53
Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma	53
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer	53
Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer	53
Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors	53
Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma	52
Immunotherapy for sarcomas: new frontiers and unveiled opportunities	52
Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes	52
Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer	51
Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells	51
Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better	51
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers	51
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor	51
MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer	51
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer	51
Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells	50
Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma	50
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy	50
Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study	50
Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma	50
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes	50
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase	50
Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis	50
CXCR6 deficiency impairs cancer vaccine efficacy and CD8+resident memory T-cell recruitment in head and neck and lung tumors	49
CXCR6 is required for antitumor efficacy of intratumoral CD8+T cell	49
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor	48
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma	48
Soluble PD-L1 as an early marker of progressive disease on nivolumab	48
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL	48
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung canc	48
WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape	47
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer	47
Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma	46
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors	46
ISA101 and nivolumab for HPV-16+cancer: updated clinical efficacy and immune correlates of response	46
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial	46
Role of immunotherapy in Ewing sarcoma	45
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma	45
MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer	45
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents	45
Comprehensive analysis of cutaneous and uveal melanoma liver metastases	45
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects	44
Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy	44
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)	44

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma	44
DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer	44
m6A modification patterns and tumor immune landscape in clear cell renal carcinoma	44
Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors	44
IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms	44
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies	44
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade	44
Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer	43
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation	43
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer	43
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells	43
Tryptophan potentiates CD8+T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation	43
In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against in	43
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade	43
PD-1+CXCR5−CD4+ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma	43
JAK inhibitors and COVID-19	43
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial	43
Landscape of natural killer cell activity in head and neck squamous cell carcinoma	42
Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects	42
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy	42
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer	42
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition	42
Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors	42
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma	42
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia	41
CD47/SIRPα axis: bridging innate and adaptive immunity	41
PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy	41
Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA	41
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study	41
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer	41
Necroptosis-driving genesRIPK1, RIPK3andMLKL-pare associated with intratumoral CD3+and CD8+T cell density and predict prognosis in hepatocellular carcinoma	40
Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer	40
Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer	40
CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment	40
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design	40
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma	40
Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment	40
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers	40
Pericardial disease in patients treated with immune checkpoint inhibitors	39
Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 anti	39
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma	39
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept	39
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study	39
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells	39
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)	39
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege	39
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)	39
Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma	39
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?	39
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors	39
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology	39
Microbial short-chain fatty acids: a strategy to tune adoptive T cell therapy	39
ZEB1 transcription factor promotes immune escape in melanoma	39
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	39
Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer	39
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	39
Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer	38
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study	38
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer	38
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing	38
MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination	38
Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab	38
Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis	38
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	38
Electrocardiographic features of immune checkpoint inhibitor associated myocarditis	37
Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy	37
Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy	37
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders	37
Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer	37
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors	37
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy	37
Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis	37
Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3	36
Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity	36
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis	36
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy	36
4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+CD8 T cells from primary and metastatic sites of epithelial ovarian cancers	36
Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis	36
An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade	36
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy	36
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone mi	36
Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis	36
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment	36
Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity	36
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy	35
Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma	35
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology	35
Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer	35
T follicular helper cells: linking cancer immunotherapy and immune-related adverse events	35
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers	35
Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4+, CD8+T cells, and M1 macrophages	35
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression	35
Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment	35
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer	34
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve	34